Retatrutide's triple receptor agonism offers complementary metabolic effects through simultaneous GLP-1, GIP, and GCG pathway activation, studied for synergistic metabolic regulation, glucose homeostasis, and weight management research.nnMechanisms: Enhanced insulin secretion, improved glucose utilization, reduced appetite signaling, increased energy expenditure, and metabolic adaptation through three hormone pathways.nnProduct Specifications: GLP-3RT Retatrutide 10mg lyophilized | 99% purity HPLC verified | Storage -20C lyophilized, 2-8C reconstituted | COA includednnResearch applications: Metabolic disease modeling, dose-response studies, glucose control pathways, weight regulation mechanisms, multi-receptor GLP/GIP/GCG activation, and metabolic syndrome reversal investigation
Sanofi Viking Therapeutics, Inc
The addition of GIP receptor activation in Retatrutide appears to improve tolerability rather than worsen it, which is consistent with what was observed in the shift from Semaglutide to Tirzepatide
News provided by Resbiotic Nutrition, Inc
Join us at our free digital summit to hear from leading experts, brands and researchers tackling the big questions: What role can food play in supporting GLP-1 users
Your genotypes are covered in detail in the genotype report section below
